A New Way To Save Lives

Help Reshape the Cardiac Bypass Surgery Procedure

Medical 21 is working on reshaping the coronary bypass surgery procedure through a innovative functional artificial vein that will eliminate the need for blood vessel harvesting.

The MAVERICS artificial graft technology has the potential to enhance the recovery and quality of life for millions of patients — and open the door for more patients to receive life-saving surgery.

Be the First To Know When We Go Live

We are currently preparing to fund our next step: bringing our technology to human trials.

Find out how you can participate in this exciting development that has the potential of changing millions of lives.

First Name (*Required)

Last Name (*Required)

Email (*Required)

Phone Number (*Required)

Company (*Optional)

Are you an accredited investor?

Yes No

Are you a caregiver to someone with cognitive loss?

Yes No

Are you a healthcare professional?

Yes No

Are you a main street investor?

Yes No

What is this message regarding? (*Required)

Message (*Required)

The form was sent successfully.

Follow Us:

The offering will be made only by means of an offering circular. An offering statement regarding this offering has been filed with the SEC. The SEC has qualified that offering statement which only means that the company may make sales of the securities described by that offering statement. It does not mean that the SEC has approved, passed upon the merits or passed upon the accuracy or completeness of the information in the offering statement. The securities offered by the company are highly speculative. Investing in shares of common stock of the company involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue. You may obtain a copy of the Form 1-A offering circular that is part of said offering statement here. You should read the offering circular before making any investment. The offering materials and this letter may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements, which constitute forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.